Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CLBT Stock Forecast 2026-2027
$13.25
Current Price
$3.31B
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CLBT Price Targets
+111.3%
To High Target of $28.00
+54.7%
To Median Target of $20.50
+35.8%
To Low Target of $18.00
CLBT Price Momentum
+5.9%
1 Week Change
-7.1%
1 Month Change
-27.9%
1 Year Change
-26.5%
Year-to-Date Change
-35.5%
From 52W High of $20.53
+20.2%
From 52W Low of $11.02
📊 TOP ANALYST CALLS
Did CLBT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cellebrite is one of their latest high-conviction picks.
Latest CLBT Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, CLBT has a bullish consensus with a median price target of $20.50 (ranging from $18.00 to $28.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $13.25, the median forecast implies a 54.7% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Mike Cikos at Needham, projecting a 111.3% upside. Conversely, the most conservative target is provided by Mike Cikos at Needham, suggesting a 35.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CLBT Analyst Ratings
7
Buy
0
Hold
0
Sell
CLBT Price Target Range
Low
$18.00
Average
$20.50
High
$28.00
Current: $13.25
Latest CLBT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CLBT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 12, 2026 | Needham | Mike Cikos | Buy | Maintains | $18.00 |
| Nov 13, 2025 | JP Morgan | Brian Essex | Overweight | Maintains | $24.00 |
| Nov 13, 2025 | B of A Securities | Tal Liani | Buy | Maintains | $25.00 |
| Nov 13, 2025 | Needham | Mike Cikos | Buy | Maintains | $24.00 |
| Nov 13, 2025 | Lake Street | Eric Martinuzzi | Buy | Maintains | $23.00 |
| Sep 24, 2025 | JP Morgan | Brian Essex | Overweight | Maintains | $23.00 |
| Aug 15, 2025 | Lake Street | Eric Martinuzzi | Buy | Maintains | $22.00 |
| Aug 14, 2025 | Needham | Mike Cikos | Buy | Maintains | $18.00 |
| Jun 23, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Jun 6, 2025 | Needham | Mike Cikos | Buy | Reiterates | $24.00 |
| May 15, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| May 14, 2025 | Needham | Mike Cikos | Buy | Maintains | $24.00 |
| May 12, 2025 | JP Morgan | Brian Essex | Overweight | Maintains | $25.00 |
| Apr 2, 2025 | Needham | Mike Cikos | Buy | Reiterates | $28.00 |
| Mar 27, 2025 | Needham | Mike Cikos | Buy | Reiterates | $28.00 |
| Mar 10, 2025 | Needham | Mike Cikos | Buy | Reiterates | $28.00 |
| Feb 14, 2025 | Needham | Mike Cikos | Buy | Reiterates | $28.00 |
| Feb 14, 2025 | Lake Street | Frank Takkinen | Buy | Maintains | $26.00 |
| Feb 11, 2025 | JP Morgan | Brian Essex | Overweight | Maintains | $28.00 |
| Jan 22, 2025 | Needham | Mike Cikos | Buy | Maintains | $28.00 |
Cellebrite DI Ltd. (CLBT) Competitors
The following stocks are similar to Cellebrite based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CLBT
Cellebrite
mkt cap
3.29B
Cellebrite DI Ltd. (CLBT) Financial Data
Cellebrite DI Ltd. has a market capitalization of $3.31B with a P/E ratio of 43.2x. The company generates $475.68M in trailing twelve-month revenue with a 16.5% profit margin.
Revenue growth is +18.1% quarter-over-quarter, while maintaining an operating margin of +16.1% and return on equity of +19.1%.
Valuation Metrics
Market Cap
$3.31B
Enterprise Value
$2.87B
P/E Ratio
43.2x
PEG Ratio
3.5x
Price/Sales
7.0x
Growth & Margins
Revenue Growth (YoY)
+18.1%
Gross Margin
+84.7%
Operating Margin
+16.1%
Net Margin
+16.5%
EPS Growth
+10.3%
Financial Health
Cash/Price Ratio
+13.2%
Current Ratio
1.6x
Debt/Equity
4.7x
ROE
+19.1%
ROA
+5.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cellebrite DI Ltd. (CLBT) Business Model
About Cellebrite DI Ltd.
What They Do
Provides digital intelligence solutions for investigations.
Business Model
Cellebrite DI Ltd. generates revenue by offering a suite of advanced digital intelligence tools and services to law enforcement, military and intelligence agencies, and enterprise clients. Their products, such as the DI suite and Universal Forensic Extraction Device, enable customers to collect and analyze digital evidence from various devices and platforms, thereby facilitating legally sanctioned investigations.
Additional Information
The company focuses on a wide range of investigative needs, including serious crimes like child exploitation and terrorism, and offers additional services such as analytics and training. Its expertise in digital forensics positions it as a key player in the growing field of digital investigations, with a diverse clientele across multiple sectors.
Company Information
Sector
Technology
Industry
Software - Infrastructure
Employees
1,167
CEO
Mr. Thomas E. Hogan
Country
Israel
IPO Year
2020
Website
www.cellebrite.comCellebrite DI Ltd. (CLBT) Latest News & Analysis
Latest News
Quick Summary
Cellebrite DI Ltd. announced news from Tysons Corner, VA, and Petah Tikva, Israel, on April 21, 2026. Further details were not provided in the excerpt.
Why It Matters
Cellebrite's announcement may indicate developments in data security or law enforcement technology, impacting tech sector investments and potential market valuations.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Cellebrite DI Ltd. hosted an event in Tysons Corner, VA, and Petah Tikva, Israel, recognizing leaders in digital investigations, showcasing industry advancements.
Why It Matters
Cellebrite's recognition in digital investigations highlights its market leadership, potentially boosting investor confidence and driving stock performance amid growing demand for digital forensics.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Cellebrite DI (CLBT) reports strong financials with 21% subscription revenue growth, $481M ARR, 34% FCF margin, and AI integration enhancing its competitive position and growth potential.
Why It Matters
Cellebrite's strong financials and AI integration position it well in a niche market, enhancing growth prospects and competitive advantage, which could lead to increased investor confidence and stock performance.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Cellebrite DI Ltd. is expanding access to its Corellium platform across various devices and operating systems, now available on Google Cloud as of March 31, 2026.
Why It Matters
Cellebrite's expansion into Google Cloud and broader device support enhances its market reach, potentially driving revenue growth and attracting new clients, which can boost investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Cellebrite (NASDAQ: CLBT) launched Guardian Investigate, an AI-driven investigative management solution, enhancing collaboration among investigators, departments, and agencies.
Why It Matters
Cellebrite's launch of Guardian Investigate enhances operational efficiency in investigations, potentially increasing demand for its solutions and boosting revenue, positively impacting stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Cellebrite (NASDAQ: CLBT) has launched Genesis, an AI product aimed at streamlining investigations, reducing task completion time from weeks to minutes.
Why It Matters
Cellebrite's new AI product Genesis could streamline investigations, enhancing efficiency and effectiveness, potentially increasing demand for its solutions and boosting revenue growth.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CLBT Stock
What is Cellebrite DI Ltd.'s (CLBT) stock forecast for 2026?
Based on our analysis of 12 Wall Street analysts, Cellebrite DI Ltd. (CLBT) has a median price target of $20.50. The highest price target is $28.00 and the lowest is $18.00.
Is CLBT stock a good investment in 2026?
According to current analyst ratings, CLBT has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.25. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CLBT stock?
Wall Street analysts predict CLBT stock could reach $20.50 in the next 12 months. This represents a 54.7% increase from the current price of $13.25. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cellebrite DI Ltd.'s business model?
Cellebrite DI Ltd. generates revenue by offering a suite of advanced digital intelligence tools and services to law enforcement, military and intelligence agencies, and enterprise clients. Their products, such as the DI suite and Universal Forensic Extraction Device, enable customers to collect and analyze digital evidence from various devices and platforms, thereby facilitating legally sanctioned investigations.
What is the highest forecasted price for CLBT Cellebrite DI Ltd.?
The highest price target for CLBT is $28.00 from Mike Cikos at Needham, which represents a 111.3% increase from the current price of $13.25.
What is the lowest forecasted price for CLBT Cellebrite DI Ltd.?
The lowest price target for CLBT is $18.00 from Mike Cikos at Needham, which represents a 35.8% increase from the current price of $13.25.
What is the overall CLBT consensus from analysts for Cellebrite DI Ltd.?
The overall analyst consensus for CLBT is bullish. Out of 12 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $20.50.
How accurate are CLBT stock price projections?
Stock price projections, including those for Cellebrite DI Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 6:32 AM UTC